Skip to main content

Table 5 Univariate analysis of potential prognostic factors associated with hepatitis in DLBCL patients with resolved hepatitis B

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Factor Without hepatitis [cases (%)] With hepatitis [cases (%)] P value
Total 43 12  
HBeAb    0.639
 – 38 (88.4) 10 (83.3)  
 + 5 (11.6) 2 (16.7)  
Age (years)    0.831
 ≤60 23 (53.5) 6 (50.0)  
 >60 20 (46.5) 6 (50.0)  
Sex    0.340
 Female 21 (48.8) 4 (33.3)  
 Male 22 (51.2) 8(66.7)  
ECOG PS    0.974
 0–1 36 (83.7) 10 (83.3)  
 ≥2 7 (16.3) 2 (16.7)  
B symptoms    0.763
 − 34 (79.1) 9 (75.0)  
 + 9 (20.9) 3 (25.0)  
Ann Arbor stage    0.168
 I–II 24 (55.8) 4 (33.3)  
 III-IV 19 (44.2) 8 (66.7)  
Liver involvement    0.447
 − 41 (95.3) 12 (100)  
 + 2 (4.7) 0 (0)  
Spleen involvement    0.873
 − 40 (93.0) 11 (91.7)  
 + 3 (7.0) 1 (8.3)  
Involved extranodal sites    0.275
 <2 35 (81.4) 8 (66.7)  
 ≥2 8 (18.6) 4 (33.3)  
Bone marrow involvement    0.594
 − 42 (97.7) 12 (100.0)  
 + 1 (2.3) 0 (0.0)  
IPI score    0.288
 0–1 18 (41.9) 3 (25.0)  
 2–5 25 (58.1) 9 (75.0)  
ALT    0.037
 ≤40 U/L 39 (90.7) 8 (66.7)  
 >40 U/L 4 (9.3) 4 (33.3)  
AST    0.005
 ≤45 U/L 41 (95.3) 8 (66.7)  
 >45 U/L 2 (4.7) 4 (33.3)  
TB    0.918
 ≤20.5 μmol/L 39 (90.7) 11 (91.7)  
 >20.5 μmol/L 4 (9.3) 1 (8.3)  
LDH    0.894
 ≤245 U/mL 26 (60.5) 7 (58.3)  
 >245 U/mL 17 (39.5) 5 (41.7)  
  1. Abbreviations as in Table 1.